ABBV vs SY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.
SY presents a contradictory profile: a stable Piotroski F-Score of 5/9 and strong liquidity, contrasted by a catastrophic earnings track record. While the company maintains a very low Price-to-Sales ratio (0.19) and healthy revenue growth (24.8% YoY), it has failed to beat earnings estimates in the last four quarters with massive negative surprises. The technical trend is completely bearish (0/100), and the shift from profitability in 2024 back to significant losses in 2025-2026 suggests a failing operational turnaround.
Compare Another Pair
Related Comparisons
ABBV vs SY: Head-to-Head Comparison
This page compares AbbVie Inc. (ABBV) and So-Young International Inc. (SY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.